ArticleMolecular biology reports2026
Are adropin gene expression levels a precursor to type 2 diabetes mellitus in prediabetic patients?
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study investigated the relationship between adropin and glucose metabolism by evaluating ENHO gene expression and serum adropin levels in individuals with Type 2 diabetes mellitus (T2DM), prediabetes, and healthy controls, and their potential as biomarkers for early diagnosis.
methodsA total of 107 participants were enrolled, including 40 T2DM patients, 26 with prediabetes, and 41 healthy controls. Serum adropin levels were measured using ELISA, and ENHO gene expression levels were assessed by quantitative real-time PCR from peripheral blood samples. Biochemical parameters, including glucose, HbA1c, insulin, HOMA-IR, triglycerides, cholesterol, HDL, and LDL, were analyzed. Statistical comparisons between groups, correlation, logistic regression, and receiver operating characteristic analyses were conducted.
resultsENHO gene expression levels were significantly higher in the prediabetes group than in controls and T2DM, whereas it was lower in T2DM patients than in controls. Serum adropin levels were significantly elevated in the T2DM group compared with prediabetes and controls, but no difference was observed between prediabetes and controls. Glucose was negatively correlated with ENHO expression in prediabetes and with serum adropin in T2DM. ENHO expression was a significant predictor of T2DM progression, demonstrating high diagnostic potential.
conclusionThe findings suggest that ENHO gene expression level may increase in prediabetes as a compensatory mechanism, whereas it decreases in T2DM, indicating disease progression. The paradoxical elevation of serum adropin in T2DM may reflect metabolic alterations. ENHO expression could serve as a potential biomarker for identifying individuals at risk of developing T2DM, warranting further large-scale studies.
Indexed as
Identifiers
42911443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.